Clinical Trial

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-07-24; most recent amendment 2025-12-21.
Status change: Recruiting → Active, Not Recruiting 2023-12-04
Status change: Not Yet Recruiting → Recruiting 2018-12-21
Trial Details
NCT Number NCT03600233
Lead Sponsor TaiRx, Inc.
Conditions Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
Enrollment 34 participants
Start Date 2018-12-15
Primary Completion 2024-09-30 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-23